Bristol Myers Squibb (BMS) has completed its acquisition of clinical-stage biopharma firm MyoKardia in an all-cash transaction for $13.1bn.

Last month, BMS signed a definitive merger agreement to purchase all the outstanding shares of MyoKardia’s common stock for $225 a share.

With the closing of the deal, MyoKardia is now a wholly owned subsidiary of BMS.

In addition, BMS has secured MyoKardia’s cardiovascular drug, mavacamten, which can potentially treat obstructive hypertrophic cardiomyopathy (HCM).

HCM is a chronic heart disease characterised by excessive contraction of the heart muscle and reduced ability of the left ventricle to fill, resulting in debilitating symptoms and cardiac dysfunction.

BMS will submit a new drug application (NDA) to the US Food and Drug Administration (FDA) in the first quarter of next year for the use of mavacamten in treating symptomatic HCM.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The submission will be based on results from the EXPLORER-HCM study.

The company plans to investigate the full potential of mavacamten in additional indications such as non-obstructive HCM.

Bristol Myers Squibb board chair and CEO Giovanni Caforio said: “With MyoKardia, we are bolstering our leading cardiovascular franchise and adding exceptional scientific capabilities, a potentially transformative new medicine with significant commercial potential and a promising pipeline of candidates.

“Cardiovascular remains an important therapeutic area for Bristol Myers Squibb with a strong legacy and a promising future.”

BMS will also develop MyoKardia’s pipeline of novel compounds that includes two clinical-stage therapeutics, namely danicamtiv and MYK-224, and two pre-clinical assets, ACT-1 and LUS-1.